Immunadsorption bei Myasthenia gravis

Köhler, Wolfgang; Bucka, C.; Hertel, G

doi:10.1055/s-2007-1017726

Cited by 3 publications

(1 citation statement)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no doubt about the first positive effect from immunoadsorption treatment of different kinds. In 1998, Köhler et al (14) published a study of the treatment of a population of 27 MG patients by IM‐TR immunosorber (Asahi Medical Cooperation, Diamed, Köln, Germany) over a period of 7 years (14). The patients also showed a lasting effect of immunoadsorption accompanied by a temporary increase of activated T cells and suppressor T cells.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Apheresis in Myasthenia Gravis Patients: A Six Year Follow‐Up

Schneidewind¹,

Zettl²,

Winkler³

et al. 1999

Therapeutic Apheresis

View full text Add to dashboard Cite

Six years ago 4 patients suffering from myasthenia gravis (MG) types C and E according to Compston with failed drug therapy were initially treated 3 times (1 patient, a total of 11 times) by protein A immunoadsorption (Immunosorba, Excorim AB, Lund, Sweden). No further immunoadsorption treatments have been carried out. In addition, 3 patients were given a thymectomy. The present status of the patients was checked. We could see a beneficial effect in all MG patients. The patients are fit for work; each has an improved Besinger index. The patients were used as their own controls. A higher anti‐AChRAb level 6 years after protein A immunoadsorption than at the beginning was seen in all patients, combined with less serious MG. In addition, their immunomodulation could be induced as seen in lymphocyte and inflammatory protein changes during the first 36 days after beginning immunoadsorption treatment. A larger population has to be investigated to verify these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Apheresis in Myasthenia Gravis Patients: A Six Year Follow‐Up

Schneidewind¹,

Zettl²,

Winkler³

et al. 1999

Therapeutic Apheresis

View full text Add to dashboard Cite

show abstract

The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy

Schneidewind

Zettl

Winkler

et al. 2001

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Therapeutic Immunoadsorption Increases the Level of Circulating Soluble HLA Molecules

Poehlau¹,

Kiltz

Rieks

et al. 2000

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives: Immunoadsorption (IA) is an established procedure to remove Igs and immune complexes from peripheral blood. Since Igs reportedly bind to human leucocyte antigen (HLA) molecules, we were interested to know whether removal of Ig will also influence the plasma concentration of soluble HLA (sHLA). Patients and Methods: Nine patients suffering from severe autoimmune disease and undergoing 17 single courses of IA treatment were monitored for their sHLA class I (sHLA–I) and sHLA–DR plasma levels. Plasma was separated by a hollow–fiber–type separator. Plasma samples were taken before therapy, after 15 min of recirculation (without operating the adsorber), after 1 and 2 liters of plasma adsorption, and 24 and 48 h after the end of IA. Results: Before treatment the mean levels of sHLA–I and sHLA–DR were 0.37 (±0.06 SEM) and 0.32±0.05 μg/ml, respectively. After 2 liters of plasma filtration, an increase in sHLA–DR (0.80±0.10 μg/ml) was observed (p<0.001), whereas sHLA–I was only slightly affected (mean: 0.45±0.06 μg/ml). sHLA concentrations returned to initial levels after 24 h. Conclusion: The significant increase in sHLA–DR may contribute to the immunomodulatory effect of IA.

show abstract

Immunadsorption bei Myasthenia gravis

Cited by 3 publications

References 4 publications

Therapeutic Apheresis in Myasthenia Gravis Patients: A Six Year Follow‐Up

Therapeutic Apheresis in Myasthenia Gravis Patients: A Six Year Follow‐Up

The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy

Therapeutic Immunoadsorption Increases the Level of Circulating Soluble HLA Molecules

Contact Info

Product

Resources

About